By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Vertex Pharmaceuticals Incorporated 

Corporate Headquarters
130 Waverly Street
Cambridge  Massachusetts  02139-4242  U.S.A.
Phone: 617-444-6100 Fax: 617-444-6680


SEARCH JOBS




The Science of Possibility.

The first thing you’ll notice about Vertex is that we are not a conventional pharmaceutical company. Each and every person at Vertex is driven by a passion for fearless innovation and a bold desire to transform the lives of millions with new medicines. Together, by creating new possibilities in medicine, our employees are quite literally changing the world.

Vertex scientists and our collaborators are working on new medicines to advance the treatment of hepatitis C, cystic fibrosis, rheumatoid arthritis and other life-threatening diseases. Our development pipeline includes several investigational drugs that have the potential to transform the treatment of serious diseases. Every day brings us a step closer to getting patients the medicines they need and potentially changing their lives in previously unimaginable ways. It’s a demanding yet incredibly rewarding experience that cannot help but change your life in the process, too.

We employ more than 2,000 of the industry’s best and brightest people at locations around the world – all of us working toward tomorrow’s breakthrough medicines.

For more information on Vertex, please visit www.vrtx.com. For information on career opportunities with Vertex, please visit www.careers.vrtx.com..

Key Contacts:
Media: mediainfo@vrtx.com
Investors: investorinfo@vrtx.com
Patient Inquiries: clinical_trials@vrtx.com


This div will be replaced


YEAR FOUNDED:

1989

LEADERSHIP:

Founder: Joshua Boger

CEO: Jeffrey Leiden

CMO (Medical): Jeffrey Chodakewitz

CFO: Ian Smith

CSO (Scientific): David Altshuler

CLINICAL TRIAL:

Please click here for clinical trial information.

FOLLOW VERTEX:




Key Statistics


Email:
Ownership: Public

Web Site: Vertex
Employees: ~1000
Symbol: VRTX
 





Collaborations

Cystic Fibrosis Foundation Therapeutics, Inc.  (VX-770 for CF)

Kissei Pharmaceutical Co., Ltd.  (VX-702 for RA)

GlaxoSmithKline  (VX-409 and Backup Compounds)

Janssen Pharmaceutica N.V.  (telaprevir for HCV) - Europe, South America, Australia, the Middle East and other countries

Merck & Co.  (MK-0457 (VX-680), MK-6592 (VX-667) and VX-689 for Cancer)

Mitsubishi Pharma Corporation  (telaprevir for HCV) - Japan and certain Far East countries





Company News
Vertex (VRTX) Reports Full-Year And Fourth-Quarter 2016 Financial Results 1/26/2017 10:55:23 AM
Earnings Preview: Here's a Look at What to Expect From 7 Biopharmas 1/23/2017 6:22:30 AM
Why Vertex (VRTX) Stock Sank 42% In 2016 1/17/2017 7:13:27 AM
Vertex (VRTX) Release: Biotech Licenses Out Four Cancer R&D Programs to Merck KGaA (MKGAF.PK) in $230 Million+ Deal 1/11/2017 7:27:48 AM
JPM17: Vertex (VRTX) Game Plan for Growth in 2017 1/10/2017 6:04:53 AM
Vertex (VRTX) Provides Update On Business And Financial Performance And Research And Development Programs 1/9/2017 11:35:45 AM
Vertex (VRTX) Announces German Reimbursement Agreement For ORKAMBI (Lumacaftor/Ivacaftor), The First Medicine To Treat The Underlying Cause Of Cystic Fibrosis In People Ages 12 And Older With Two Copies Of The F508del Mutation 12/19/2016 10:31:52 AM
Vertex (VRTX)'s Orkambi Met Primary Endpoint in Phase III Study for Kids With CF 11/7/2016 8:56:25 AM
Mom To Vertex (VRTX) -"We're Middle Class And We're Screwed" 10/28/2016 7:37:07 AM
Vertex (VRTX) Presents Long-Term Data Demonstrating That ORKAMBI (Lumacaftor/Ivacaftor) And KALYDECO (Ivacaftor) Show The Potential To Modify The Progression Of CF 10/27/2016 10:58:27 AM
12345678910...
//-->